CTLA4 and neoplasm: As intratumorally administered oncolytic Ads primarily exert their therapeutic effect in the tumor tissues, the overlapping site of T cell activation by αPD-1 could be more beneficial than systemic immune activation by CTLA-4 in controlling primary tumors.